Waldron Private Wealth’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Waldron Private Wealth’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,981	Closed	-$14.7K	–	430
2023 Q1	$14.7K	Hold	3,981	–	–	﹤0.01%	419
2022 Q4	$31K	Hold	3,981	–	–	﹤0.01%	363
2022 Q3	$31K	Hold	3,981	–	–	﹤0.01%	366
2022 Q2	$83K	Hold	3,981	–	–	﹤0.01%	372
2022 Q1	$149K	Buy	3,981 +2,977	+297%	+$103K	0.01%	388
2021 Q4	$56K	Hold	1,004	–	–	﹤0.01%	370
2021 Q3	$72K	Hold	1,004	–	–	﹤0.01%	351
2021 Q2	$96K	Buy	+1,004	New	+$111K	0.01%	330

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Waldron Private Wealth's NBSE Position: Q2 2023 in Review

Waldron Private Wealth sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 3,981 shares — an estimated $14.7K sold.

Waldron Private Wealth first reported a position in NBSE in Q2 2021 and held it in 8 quarters. The position peaked at $149K in Q1 2022. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Waldron Private Wealth reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Waldron Private Wealth sold 3,981 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $14.7K.
Waldron Private Wealth first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Waldron Private Wealth's NeuBase Therapeutics, Inc. Common Stock position peaked at $149K in Q1 2022.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Waldron Private Wealth's 13F filing for Q2 2023, filed 7 Aug 2023.